ImmuniyBio is eyeing a move up the non-muscle invasive bladder cancer (NMIBC) treatment line for its immunotherapy Anktiva. ...

Summit Therapeutics is gearing up for ivonescimab’s high-stakes FDA decision without its chief commercial officer (CCO) ...

Johnson & Johnson is gearing up to expand the commercial reach of Caplyta after scoring a second phase 3 victory in bipolar ...

Following a back-and-forth with the Pentagon this year, contracting juggernaut WuXi AppTec appears to have largely evaded its ...

Vertex has decided to lay off 78 employees at Crinetics Pharmaceuticals following its $10 billion acquisition of the ...

The FDA is requiring an update to the labels of 12 different GLP-1 receptor agonists after a deep dive by the agency ...

Phillips Medisize, a Molex subsidiary CDMO that focuses on inhalation products and other medical and diagnostic products, is ...

Shortly after locking down a world-first approval in China, Bayer is bringing its groundbreaking stroke prevention drug ...

In a new readout of 12-month data, Veradermics' oral minoxidil delivered the best hair growth data of its phase 3 program so ...

The FDA has launched a safety investigation into Novartis’ gene therapy Zolgensma following reports of tumors in patients, as ...

Eli Lilly could soon see two label expansions for Foundayo, it’s oral GLP-1, in swift succession: In September, the drugmaker ...

Johnson & Johnson’s much-hyped Icotyde pill shows another biologic-like efficacy in inflammatory diseases, with a phase 3 win ...